# Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct06141980` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06141980](<https://clinicaltrials.gov/study/NCT06141980>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06141980

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 134 participants.

## Technical summary

Registry record NCT06141980. Allocation not applicable; no masking; primary purpose treatment. Start 2023-12 (anticipated); primary completion 2025-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 134 participants (planned count; ClinicalTrials.gov record NCT06141980, source copy `cardio:ctgov-nct06141980-2023-11-21`, retrieved 2026-10-26)
- Planned start: 2023-12 (anticipated) (ClinicalTrials.gov record NCT06141980, source copy `cardio:ctgov-nct06141980-2023-11-21`, retrieved 2026-10-26)
- Primary completion: 2025-09 (anticipated) (ClinicalTrials.gov record NCT06141980, source copy `cardio:ctgov-nct06141980-2023-11-21`, retrieved 2026-10-26)
- Completion: 2025-09 (anticipated) (ClinicalTrials.gov record NCT06141980, source copy `cardio:ctgov-nct06141980-2023-11-21`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06141980-2023-11-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus
- Condition: T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug): DWP16001 0.3 mg
- Lead sponsor: Daewoong Pharmaceutical Co. LTD.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Daewoong Pharmaceutical Co. LTD. (`cardio:org-daewoong-pharmaceutical-co-ltd`)

## Provenance

Content hash: 5f484b03ce92de394b08aad60891e24b13fe5ac4e506e0d49a9615df341e3d1f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
